The FDA has accepted Roche's application for fenebrutinib and placed it on priority review, which typically spans about six months. The BTK inhibitor met primary endpoints in three Phase 3 trials and is being evaluated for both relapsing and primary progressive MS. Regulators will closely examine safety signals, including a Hy's Law liver event and eight deaths across two Phase 3 studies versus one in the comparator arm. Roche says the deaths had varied causes and describes the overall safety profile as manageable across a development database of more than 2,700 participants.
FDA Accepts Roche’s MS Pill Fenebrutinib, Begins Priority Review Amid Safety Questions
The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
The Food and Drug Administration has accepted Roche's application for fenebrutinib, an experimental oral Bruton's tyrosine kinase (BTK) inhibitor for multiple sclerosis, and placed the submission on priority review. The agency will evaluate the drug for both relapsing MS and primary progressive MS, potentially making fenebrutinib the first BTK inhibitor approved in both settings if cleared.
Regulatory Timeline
The FDA's priority review typically shortens the review clock to about six months. Roche has not provided a specific target decision date, but the designation signals the agency considers fenebrutinib a therapy that could address an important unmet medical need in MS.
Trial Results
Roche's application is supported by three Phase 3 trials that met their primary endpoints. Across the development program, the company cites a safety database that includes more than 2,700 study participants.
Safety Signals Under Review
Regulators will scrutinize notable safety findings from the Phase 3 studies. Roche reported one case in which liver enzyme elevations met the threshold defined as Hy's Law, a marker associated with an elevated risk of severe liver injury or the need for transplantation. Additionally, there were eight deaths among participants randomized to fenebrutinib across two of the three Phase 3 trials, compared with one death in the arm receiving the comparator drug, Aubagio.
Roche said the deaths occurred at different timepoints and had various causes, and the company characterizes the overall safety profile as manageable within its larger database. The program was also previously slowed by a partial clinical hold, which has since been addressed.
Context In The BTK Field
Fenebrutinib joins a wave of BTK inhibitors being tested for autoimmune diseases. Results in this class have been mixed: Novartis and Sanofi recently secured approvals for certain immune conditions, while programs from Merck KGaA and Sanofi encountered liver-related adverse events and missed primary goals in relapsing MS trials. Sanofi's candidate Cenrifki was rejected by U.S. regulators in part due to safety concerns and later approved in Europe for a narrower MS population.
What Comes Next
The FDA will weigh the efficacy data against the safety signals when making its decision. If the agency grants approval, fenebrutinib could become an important option for patients with relapsing and primary progressive MS, but the review will hinge on whether benefits outweigh potential risks.
Roche statement: The company maintains that the overall safety profile is manageable based on its clinical database of more than 2,700 participants.
Help us improve.
